VA Premier CompleteCare Drugs that Require Step Therapy Last Updated: 09/23/2014

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "VA Premier CompleteCare Drugs that Require Step Therapy Last Updated: 09/23/2014"

Transcription

1 Atelvia Atelvia Claim will pay automatically for Atelvia if enrollee has a paid claim for at least a 1 days supply of alendronate in the past 365 days. Otherwise, Atelvia requires a step therapy exception request indicating: (1) history of inadequate treatment response with alendronate, OR (2) history of adverse event with alendronate, OR (3) alendronate is contraindicated. Effective Date: 10/01/2014 Page 1 of 14

2 Aubagio Aubagio Claim will pay automatically for aubagio if enrollee has a paid claim for at least a 1 days supply of MITOXANTRONE, REBIF, COPAXONE, or Betaseron in the past 365 days. Otherwise, aubagio requires a step therapy exception request indicating: (1) history of inadequate treatment response with MITOXANTRONE, REBIF, COPAXONE, or Betaseron, OR (2) history of adverse event with MITOXANTRONE, REBIF, COPAXONE, or Betaseron, OR (3) MITOXANTRONE, REBIF, COPAXONE, or Betaseron is contraindicated. Effective Date: 10/01/2014 Page 2 of 14

3 Brintellix Brintellix Claim will pay automatically for brintellix if enrollee has a paid claim for at least a 1 days supply of any 2 generic formulary antidepressants in the past 365 days. Otherwise, brintellix requires a step therapy exception request indicating: (1) history of inadequate treatment response with any 2 generic formulary antidepressants, OR (2) history of adverse event with any 2 generic formulary antidepressantss, OR (3) any 2 generic formulary antidepressants are contraindicated. Effective Date: 10/01/2014 Page 3 of 14

4 Celebrex Celebrex Claim will pay automatically for Celebrex if enrollee has a paid claim for at least a 1 days supply of Generic NSAID tablets or capsules in the past 365 days. Otherwise, Celebrex requires a step therapy exception request indicating: (1) history of inadequate treatment response with oral NSAIDs, OR (2) history of adverse event with oral NSAIDs, OR (3) oral NSAIDs are contraindicated. Effective Date: 10/01/2014 Page 4 of 14

5 Dexilant Dexilant Claim will pay automatically for Dexilant if enrollee has a paid claim for at least a 1 days supply of omeprazole or pantoprazole in the past 365 days. Otherwise, Dexilant requires a step therapy exception request indicating: (1) history of inadequate treatment response with omeprazole or pantoprazole, OR (2) history of adverse event with omeprazole or pantoprazole, OR (3) omeprazole or pantoprazole is contraindicated. Effective Date: 10/01/2014 Page 5 of 14

6 Dificid Dificid Claim will pay automatically for Dificid if enrollee has a paid claim for at least a 1 days supply of Generic Vancomycin capsules in the past 120 days. Otherwise, Dificid requires a step therapy exception request indicating: (1) history of inadequate treatment response with Vancomycin, OR (2) history of adverse event with Vancomycin, OR (3) Vancomycin is contraindicated. Effective Date: 10/01/2014 Page 6 of 14

7 Edari Edarbi Claim will pay automatically for Edarbi if enrollee has a paid claim for at least a 1 days supply of losartan in the past 365 days. Otherwise, Edarbi requires a step therapy exception request indicating: (1) history of inadequate treatment response with losartan, OR (2) history of adverse event with losartan, OR (3) losartan is contraindicated. Effective Date: 10/01/2014 Page 7 of 14

8 Edarychlor Edarbyclor Claim will pay automatically for Edarbychlor if enrollee has a paid claim for at least a 1 days supply of losartan/hctz or Edarbi in the past 365 days. Otherwise, Edarbychlor requires a step therapy exception request indicating: (1) history of inadequate treatment response with losartan/hctz or Edarbi, OR (2) history of adverse event with losartan/hctz or Edarbi, OR (3) losartan/hctz or Edarbi is contraindicated. Effective Date: 10/01/2014 Page 8 of 14

9 Enablex Enablex Claim will pay automatically for Enablex if enrollee has a paid claim for at least a 1 days supply of any generic formulary urinary anticholinergic in the past 365 days. Otherwise, Enablex requires a step therapy exception request indicating: (1) history of inadequate treatment response with generic formulary urinary anticholinergic, OR (2) history of adverse event with generic formulary urinary anticholinergic, OR (3) generic formulary urinary anticholinergic is contraindicated. Effective Date: 10/01/2014 Page 9 of 14

10 Fentanyl Fentanyl Transdermal Patch Claim will pay automatically for Fentanyl patches if enrollee has paid claims history for both Group A and Group B drugs. GROUP A Drugs: Any 1 days supply in the past 365 days of generic Oxymorphone ER (2) GROUP B Drugs: Any 1 days supply in the past 365 days of either Morphine ER or Methadone. Otherwise, the drug requires a step therapy exception request indicating any ONE of the following: (1) history of inadequate treatment response with Group A or Group B drugs, OR (2) history of adverse event with Group A or Group B drugs, OR (3) Group A or Group B drugs are contraindicated. Effective Date: 10/01/2014 Page 10 of 14

11 High Potency Statin Crestor Patient needs to have a paid claim for a Step 1 drug (atorvastatin) prior to filling a Step 2 drug (Crestor). Effective Date: 10/01/2014 Page 11 of 14

12 Myrbetriq Myrbetriq Claim will pay automatically for Myrbetriq if enrollee has a paid claim for at least a 1 days supply of any formulary urinary anticholinergic in the past 365 days. Otherwise, Myrbetriq requires a step therapy exception request indicating: (1) history of inadequate treatment response with formulary urinary anticholinergic, OR (2) history of adverse event with formulary urinary anticholinergic, OR (3) formulary urinary anticholinergic is contraindicated. Effective Date: 10/01/2014 Page 12 of 14

13 Uceris Uceris Claim will pay automatically for Uceris if enrollee has a paid claim for at least a 1 days supply of any formulary corticosteroid used to treat ulcerative colitis in the past 365 days. Otherwise, Uceris requires a step therapy exception request indicating: (1) history of inadequate treatment response with formulary corticosteroid used to treat ulcerative colitis, OR (2) history of adverse event with formulary corticosteroid used to treat ulcerative colitis, OR (3) formulary corticosteroid used to treat ulcerative colitis is contraindicated. Effective Date: 10/01/2014 Page 13 of 14

14 Uloric Uloric Claim will pay automatically for Uloric if enrollee has a paid claim for at least a 1 days supply of Allopurinol in the past 365 days. Otherwise, Uloric requires a step therapy exception request indicating: (1) history of inadequate treatment response with Allopurinol, OR (2) history of adverse event with Allopurinol, OR (3) Allopurinol is contraindicated. Effective Date: 10/01/2014 Page 14 of 14

AUBAGIO. Step Therapy Criteria Health Choice Generations Formulary ID: 15179 Version 19 Effective Date: 11/1/2015. PRODUCT(s) AFFECTED AUBAGIO

AUBAGIO. Step Therapy Criteria Health Choice Generations Formulary ID: 15179 Version 19 Effective Date: 11/1/2015. PRODUCT(s) AFFECTED AUBAGIO AUBAGIO AUBAGIO Claim will pay automatically for AUBAGIO if enrollee has a paid claim for at least a 1 days supply of COPAXONE, REBIF, TYSABRI, BETASERON OR EXTAVIA in the past 365 days. Otherwise, AUBAGIO

More information

Aubagio. AgeWell Drugs that Require Step Therapy Last Updated: 08/08/2014. Products Affected. Details AUBAGIO TAB 14MG AUBAGIO TAB 7MG

Aubagio. AgeWell Drugs that Require Step Therapy Last Updated: 08/08/2014. Products Affected. Details AUBAGIO TAB 14MG AUBAGIO TAB 7MG Aubagio AUBAGIO TAB 14MG AUBAGIO TAB 7MG Claim will pay automatically for AUBAGIO if enrollee has a paid claim for at least a 1 days supply of COPAXONE, REBIF, TYSABRI, BETASERON OR EXTAVIA in the past

More information

ACTEMRA. Step Therapy Criteria HEALTH CHOICE EXCHANGE 2016 Effective Date: 01/01/2016. PRODUCT(s) AFFECTED ACTEMRA

ACTEMRA. Step Therapy Criteria HEALTH CHOICE EXCHANGE 2016 Effective Date: 01/01/2016. PRODUCT(s) AFFECTED ACTEMRA ACTEMRA ACTEMRA Claim will pay automatically for Actemra if enrollee has a paid claim for at least a 1 days supply of Enbrel and Humira in the past 365 days. Otherwise, Actemra requires a step therapy

More information

2014 Valley Baptist Medicare D Formulary Step Therapy Criteria

2014 Valley Baptist Medicare D Formulary Step Therapy Criteria 2014 Valley Baptist Medicare D Formulary Step Therapy Products Affected ACTONEL TAB Last Updated 11/1/2014 Requires a trial of alendronate. 1 APLENZIN TAB Patient must have tried bupropion SR or bupropion

More information

Plan Year Allegian Advantage (HMO) Step Therapy Criteria (ST)

Plan Year Allegian Advantage (HMO) Step Therapy Criteria (ST) Plan Year 2015 Allegian Advantage (HMO) Step Therapy (ST) Step Therapy: In some cases, Allegian Advantage requires you to first try certain drugs to treat your medical condition before we will cover another

More information

2015 Medicare Part D Step Therapy Requirements. Effective: November 01, 2015

2015 Medicare Part D Step Therapy Requirements. Effective: November 01, 2015 2015 Medicare Part D Step Therapy Requirements Effective: November 01, 2015 Formulary ID 15293, Version 17 Last Updated: 10/27/2015 BISPHOSPHONATE THERAPY ACTONEL 30 MG TABLET ACTONEL 35 MG TABLET ACTONEL

More information

Prescribing Pathway for Drug Treatment for Overactive Bladder.

Prescribing Pathway for Drug Treatment for Overactive Bladder. East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG - Prescribing Clinical Network

More information

Pharmacotherapy: opioids, NSAIDs, adjuvants, and analgesic e...

Pharmacotherapy: opioids, NSAIDs, adjuvants, and analgesic e... 1. : opioids, NSAIDs, adjuvants, and analgesic e... 2. of Pain Page - 1 3. Mechanisms of Pain and Medication Activity Sites 4. Classes of analgesics Page - 2 5. Severity: WHO analgesic ladder 6. Pain Source

More information

MEDICATION(S) SUBJECT TO STEP THERAPY

MEDICATION(S) SUBJECT TO STEP THERAPY ACE/ARB COMBO AZOR 5-20 MG TABLET, AZOR 5-40 MG TABLET, BENICAR HCT, MICARDIS HCT, TARKA, TEKTURNA HCT, TELMISARTAN-HYDROCHLOROTHIAZID, TRIBENZOR Claims for formulary step 2 ACE Inhibitor combination products

More information

AETNA BETTER HEALTH Prior Authorization guidelines for Step Therapy

AETNA BETTER HEALTH Prior Authorization guidelines for Step Therapy AETNA BETTER HEALTH Prior Authorization guidelines for Step Therapy Definition A form of automated Prior Authorization whereby one or more prerequisite medications, which may or may not be in the same

More information

ALZHEIMER'S DRUGS. Details. Step 2: Exelon Patch 13.3 mg/24 hour transdermal Exelon Patch 4.6 mg/24 hr transdermal

ALZHEIMER'S DRUGS. Details. Step 2: Exelon Patch 13.3 mg/24 hour transdermal Exelon Patch 4.6 mg/24 hr transdermal ALZHEIMER'S DRUGS Products Affected Step 1: donepezil 10 mg disintegrating tablet donepezil 10 mg tablet donepezil 23 mg tablet donepezil 5 mg disintegrating tablet donepezil 5 mg tablet galantamine 12

More information

2016 Step Therapy Criteria

2016 Step Therapy Criteria 2016 Step Therapy Criteria ANGIOTENSIN RECEPTOR BLOCKERS... 8 benazepril... 8 benazepril/amlodipine besylate... 8 benazepril/hctz... 8 captopril... 8 captopril/hctz... 8 enalapril... 8 enalapril maleate/hctz...

More information

West Virginia Medicaid PDL Recommended Changes Summary Pharmaceutical and Therapeutics Committee Meeting January 26, 2011

West Virginia Medicaid PDL Recommended Changes Summary Pharmaceutical and Therapeutics Committee Meeting January 26, 2011 West Virginia Medicaid PDL Recommended Changes Summary Pharmaceutical and Therapeutics Committee Meeting January 26, 2011 TOPIC Current PDL Status ACNE AGENTS, TOPICAL 4/1/11 Planned PDL Status Recommend

More information

this 7^ day of September 2014 by Randall S. Gregg Special Deputy Director

this 7^ day of September 2014 by Randall S. Gregg Special Deputy Director r STATE OF MICHIGAN DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES Before the Director of Insurance and Financial Services In the matter of: Petitioner, v File No. 143525-001 Health Alliance Plan of Michigan,

More information

Blueprint for Prescriber Continuing Education Program

Blueprint for Prescriber Continuing Education Program CDER Final 10/25/11 Blueprint for Prescriber Continuing Education Program I. Introduction: Why Prescriber Education is Important Health care professionals who prescribe extended-release (ER) and long-acting

More information

The TIRF REMS Access program is a Food and Drug Administration (FDA) required risk management program

The TIRF REMS Access program is a Food and Drug Administration (FDA) required risk management program Subject: Important Drug Warning Announcement of a single shared REMS (Risk Evaluation and Mitigation Strategy) program for all Transmucosal Immediate Release Fentanyl (TIRF) products due to the potential

More information

Pain Management in Palliative and Hospice Care

Pain Management in Palliative and Hospice Care Pain Management in Palliative and Hospice Care Donna Butler, MSN, ANP-BC, OCN, ACHPN, FAAPM Current Status of Pain Cancer patients at EOL- 54% have pain AIDS with prognosis < 6mons- intense pain Less research

More information

OPIOIDS CONVERSION GUIDELINES 2007

OPIOIDS CONVERSION GUIDELINES 2007 Opioid analgesics vary in potency, side effect and pharmacokinetic profile. Therefore the Opioid Conversion Guidelines has been developed to assist when changing opioid drug therapy. When opioid rotating

More information

Narcotic drugs used for pain treatment Version 4.3

Narcotic drugs used for pain treatment Version 4.3 Narcotic drugs used for pain treatment Version 4.3 Strategy to restrict the pack sizes or the type of packaging available in public pharmacies. 1. Introduction The document describing the strategy of the

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy PAGE: Page 1 of 9 DESCRIPTION: Step Therapy encourages use of safe, cost-effective medications within different therapeutic drug categories. The entry of new generics and cost-effective therapeutic alternatives

More information

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January

More information

Department of Vermont Health Access Pharmacy Benefit Management Program DUR Board Meeting Minutes: 03/11/2014

Department of Vermont Health Access Pharmacy Benefit Management Program DUR Board Meeting Minutes: 03/11/2014 Department of Vermont Health Access Pharmacy Benefit Management Program DUR Board Meeting Minutes: 03/11/2014 Board Members: Present: Joseph Lasek, MD, Chair Gary Starecheski, RPh Mark Pasanen, MD James

More information

Opioid Use in the Elderly

Opioid Use in the Elderly Opioid Use in the Elderly CRIT in the Care of Older Adults Mellissa Ubbens, PharmD, BCPS Clinical Pharmacist, Duke University Hospital Acknowledgements Thank you to Jason Moss, PharmD, CGP and Jen Gommer,

More information

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary November 1, 2014 Bulletin #150 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary New Exception Drug Status (EDS) Listings Effective November 1, 2014

More information

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January

More information

Prescription Drug Utilization and Cost Trends, 2009-2013

Prescription Drug Utilization and Cost Trends, 2009-2013 Agenda Item 7 Attachment 1 Prescription Drug Utilization and Cost Trends, 2009-2013 Pension and Health Benefits Committee October 14, 2014 Melissa Mantong, PharmD CalPERS Pharmacist Overview Trends in

More information

Table 1 Performance Measures. Quality Monitoring P4P Yr1 Yr2 Yr3. Specification Source. # Category Performance Measure

Table 1 Performance Measures. Quality Monitoring P4P Yr1 Yr2 Yr3. Specification Source. # Category Performance Measure Table 1 Performance Measures # Category Performance Measure 1 Behavioral Health Risk Assessment and Follow-up 1) Behavioral Screening/ Assessment within 60 days of enrollment New Enrollees who completed

More information

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January

More information

Pain management. The WHO analgesic ladder

Pain management. The WHO analgesic ladder Pain management Successful treatment requires an accurate diagnosis of the cause and a rational approach to therapy. Most pains arise by stimulation of nociceptive nerve endings; the characteristics may

More information

Pain is a symptom people associate with a malignant illness and is common in non malignant disease.

Pain is a symptom people associate with a malignant illness and is common in non malignant disease. HAWKE S BAY DISTRICT HEALTH BOARD Manual: Clinical Guidelines Manual CRANFORD HOSPICE Doc No: HBDHB/IVTG/139 Issue Date: Review Date: 3 yearly Approved: Cranford Hospice Medical Pain in the Palliative

More information

POST-TEST Pain Resource Professional Training Program University of Wisconsin Hospital & Clinics

POST-TEST Pain Resource Professional Training Program University of Wisconsin Hospital & Clinics POST-TEST University of Wisconsin Hospital & Clinics True/False/Don't Know - Circle the correct answer T F D 1. Changes in vital signs are reliable indicators of pain severity. T F D 2. Because of an underdeveloped

More information

SELECTED OPIATES TOXICITY A MODERN DAY EPIDEMIC

SELECTED OPIATES TOXICITY A MODERN DAY EPIDEMIC SELECTED OPIATES TOXICITY A MODERN DAY EPIDEMIC Learning Objectives: 1. Identify the names and reasons/circumstances for additional toxicity of SELECTED OPIATES hydromorphone DILAUDID Methadone Fentanyl/DURAGESIC

More information

Acetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD)

Acetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD) SHARED CARE PROTOCOL AND INFORMATION FOR GPS Acetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD) Version: 3 Date Approved: June 2011 Review

More information

UPDATED INVESTOR PRESENTATION June 2015

UPDATED INVESTOR PRESENTATION June 2015 UPDATED INVESTOR PRESENTATION June 2015 Forward-looking Statements All statements in this presentation other than those of historical fact, including statements regarding our clinical development plans

More information

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Medication Policy Manual Policy No: dru229 Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January

More information

Effective January 1, 2016

Effective January 1, 2016 Effective January 1, 2016 CONTENTS Prescription Benefit Changes...2 2016 Prescription Drug Benefit Highlights...3 Comparing Your Options...4 Filling Your Prescriptions...4 Benefit Coverage Tiers...5 Prescription

More information

Hospice & Palliative Care in Developing Countries

Hospice & Palliative Care in Developing Countries Hospice & Palliative Care in Developing Countries Compounding End of Life Medications WHO Recommendations to Developing Countries Russ Zakarian, Pharm.D. FASCP What is Compounding? Compounding is the method

More information

APRIL 2015 THE 2014 DRUG TREND REPORT WORKERS COMPENSATION

APRIL 2015 THE 2014 DRUG TREND REPORT WORKERS COMPENSATION APRIL 2015 THE 2014 DRUG TREND REPORT WORKERS COMPENSATION CONTENTS INTRODUCTION 3 2014 Highlights Introduction Opioid Medication Use Compounded Medications Physician Dispensing Network Penetration and

More information

Growth in revenue from MS drugs has been driven largely by price increases over the last several years.

Growth in revenue from MS drugs has been driven largely by price increases over the last several years. March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera

More information

Patient Tools: What You Need to Know about Paying for Your Osteoporosis Medications. February 2012. Developed by the National Osteoporosis Foundation

Patient Tools: What You Need to Know about Paying for Your Osteoporosis Medications. February 2012. Developed by the National Osteoporosis Foundation Patient Tools: about Paying for Your Osteoporosis Medications Developed by the National Osteoporosis Foundation February 2012 Paying for Your Osteoporosis Medications: What You Need to Know How much your

More information

ALASKA MEDICAID PHARMACY AND THERAPEUTICS COMMITTEE. Location of Meeting Frontier Building, 3601 C Street, room 890/896

ALASKA MEDICAID PHARMACY AND THERAPEUTICS COMMITTEE. Location of Meeting Frontier Building, 3601 C Street, room 890/896 Page 1 of 22 ALASKA MEDICAID PHARMACY AND THERAPEUTICS COMMITTEE Location of Meeting Frontier Building, 3601 C Street, room 890/896 MINUTES OF MEETING 8:00 a.m. Committee Members Present: Dharma Begich,

More information

Background. 1 4/6/2012 Steven Chen, PharmD; Sun Han, PharmD, USC School of Pharmacy

Background. 1 4/6/2012 Steven Chen, PharmD; Sun Han, PharmD, USC School of Pharmacy University of Southern California School of Pharmacy Medication Therapy Intervention & Safety Documentation Program User Manual (v 7.0, last updated 4/6/2012) Steven Chen, Pharm.D., Associate Professor

More information

Reducing Narcotics Misuse and Abuse in Workers Compensation

Reducing Narcotics Misuse and Abuse in Workers Compensation Reducing Narcotics Misuse and Abuse in Workers Compensation Trusted. Reliable. Sustainable. Page 2 Introduction Narcotics have a long history of being used to therapeutically treat pain resulting from

More information

OFFICE OF THE ASSISTANT SECRETARY OF DEFENSE HEALTH AFFAIRS 7700 ARLINGTON BOULEVARD, SUITE 5101 FALLS CHURCH, VIRGINIA 22042-5101

OFFICE OF THE ASSISTANT SECRETARY OF DEFENSE HEALTH AFFAIRS 7700 ARLINGTON BOULEVARD, SUITE 5101 FALLS CHURCH, VIRGINIA 22042-5101 OFFICE OF THE ASSISTANT SECRETARY OF DEFENSE HEALTH AFFAIRS 7700 ARLINGTON BOULEVARD, SUITE 5101 FALLS CHURCH, VIRGINIA 22042-5101 DEFENSE HEALTH AGENCY 69 091198200001401017 20104 201311982 14 JOHN Q

More information

PHARMACOLOGY UPDATE: BOOMER DRUGS

PHARMACOLOGY UPDATE: BOOMER DRUGS PHARMACOLOGY UPDATE: BOOMER DRUGS Sandra Brownstein, PharmD Evercare Clinical Pharmacy Director West Region Objectives: Review the new drugs that have recently been approved by the FDA Determine the role

More information

612 Program Midtown Express Pharmacy

612 Program Midtown Express Pharmacy ALENDRONATE SOD TAB 35MG (max 1 per week) $37.00 $70.00 ALENDRONATE SOD TAB 70MG (max 1 per week) $37.00 $70.00 ALLOPURINOL TAB 100MG $20.00 $38.00 ALLOPURINOL TAB 300MG $20.00 $38.00 AMITRIPTYLINE TAB

More information

Notice from the Executive Officer: Supporting Sustainability and Access for the Ontario Drug Benefit Program

Notice from the Executive Officer: Supporting Sustainability and Access for the Ontario Drug Benefit Program Ontario Public Drug Programs, Ministry of Health and Long-Term Care Notice from the Executive Officer: Supporting Sustainability and Access for the Ontario Drug Benefit Program Responsible management of

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF I. Requirements for Prior Authorization of Tysabri A. Prescriptions That Require Prior Authorization All prescriptions for Tysabri must be prior authorized.

More information

55 What are the rules for promoting medications to consumers in the U.S.?

55 What are the rules for promoting medications to consumers in the U.S.? Chapter 55 What are the rules for promoting medications to consumers in the U.S.? The U.S. and New Zealand are the only two countries that allow the directto-consumer (DTC) advertising of prescription

More information

September 2014. Strategy or Medications Added or Modified Remove belladonna alkaloidsphenobarbital. Therapeutic Class/Drug Name.

September 2014. Strategy or Medications Added or Modified Remove belladonna alkaloidsphenobarbital. Therapeutic Class/Drug Name. The following changes to the Neighborhood formulary were recently approved by the Pharmacy and s (P&T) Committee. These changes are effective immediately unless otherwise indicated. Belladonna alkaloidsphenobarbital

More information

Potential Savings from Generic Drugs in Upstate New York

Potential Savings from Generic Drugs in Upstate New York T H E F A C T S A B O U T Potential Savings from Generic Drugs in Upstate New York $880 Million in Potential Savings for Upstate New York Counties Finger Lakes Region $141 million Western New York Region

More information

Immune Modulating Drugs Prior Authorization Request Form

Immune Modulating Drugs Prior Authorization Request Form Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia Ref No. E040 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1.

More information

Community Pharmacists in NHS Rotherham

Community Pharmacists in NHS Rotherham SERVICE LEVEL AGREEMENT TO ENABLE COMMUNITY PHARMACISTS IN NHS ROTHERHAM TO PROVIDE PALLIATIVE CARE DRUGS AS LOCAL ENHANCED SERVICE PREPARED BY: NHS Rotherham CCG Medicines Management Team on behalf of

More information

Richard C. Dart, MD, PhD Denver Health & Hospital Authority Professor, University of Colorado School of Medicine

Richard C. Dart, MD, PhD Denver Health & Hospital Authority Professor, University of Colorado School of Medicine Richard C. Dart, MD, PhD Denver Health & Hospital Authority Professor, University of Colorado School of Medicine Goal: Minimize abuse and diversion (MAD) while providing pain control for patients. A claim

More information

Lumbar Fusion. Reference Guide for PACU CLINICAL PATHWAY. All patient variances to the pathway are to be circled and addressed in the progress notes.

Lumbar Fusion. Reference Guide for PACU CLINICAL PATHWAY. All patient variances to the pathway are to be circled and addressed in the progress notes. Reference Guide for PACU Lumbar Fusion CLINICAL PATHWAY All patient variances to the pathway are to be circled and addressed in the progress notes. This Clinical Pathway is intended to assist in clinical

More information

PARTNERSHIP HEALTHPLAN RECOMMENDATIONS For Safe Use of Opioid Medications

PARTNERSHIP HEALTHPLAN RECOMMENDATIONS For Safe Use of Opioid Medications PARTNERSHIP HEALTHPLAN RECOMMENDATIONS For Safe Use of Opioid Medications Primary Care & Specialist Prescribing Guidelines Introduction Partnership HealthPlan is a County Organized Health System covering

More information

Drug Formulary Update, July 2013

Drug Formulary Update, July 2013 Drug Formulary Update, July 2013 Updates to the HealthPartners Drug Formularies are listed below. Updates for the Commercial Drug Formularies and the Minnesota Health Care Programs (Medicaid and Minnesota

More information

Abstral Prescriber and Pharmacist Guide

Abstral Prescriber and Pharmacist Guide Abstral Prescriber and Pharmacist Guide fentanyl citrate sublingual tablets Introduction The Abstral Prescriber and Pharmacist Guide is designed to support healthcare professionals in the diagnosis of

More information

Overall Drug Trends in. Artemis Emslie VP of Pharmacy Product Development

Overall Drug Trends in. Artemis Emslie VP of Pharmacy Product Development Overall Drug Trends in Workers Compensation Artemis Emslie VP of Pharmacy Product Development Workers compensation PBM industry overview PBM's addressable market approximates $5 billion and is growing

More information

Updates to the Alberta Human Services Drug Benefit Supplement

Updates to the Alberta Human Services Drug Benefit Supplement Updates to the Alberta Human Services Drug Benefit Supplement Effective December 1, 2014 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone

More information

Insight. Drug Class. Background, new developments, key strategies. Introduction. Faulty signals. 400,000 patients in the US 1

Insight. Drug Class. Background, new developments, key strategies. Introduction. Faulty signals. 400,000 patients in the US 1 Drug Class Insight Multiple Sclerosis Background, new developments, key strategies Introduction 400,000 patients in the US 1 Most people diagnosed between age 20 50 2 2-3x more women than men get MS 2

More information

PHARMACEUTICAL MANAGEMENT PROCEDURES

PHARMACEUTICAL MANAGEMENT PROCEDURES PHARMACEUTICAL MANAGEMENT PROCEDURES THE FORMULARY The purpose of Coventry Health Care s formulary is to encourage use of the most cost-effective drugs. The formulary is necessary because the cost of prescription

More information

Education Program for Prescribers and Pharmacists

Education Program for Prescribers and Pharmacists Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists Products Covered Under This Program Abstral (fentanyl)

More information

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013 Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.

More information

Global Multiple Sclerosis Market: Trends and Opportunities (2013-18)

Global Multiple Sclerosis Market: Trends and Opportunities (2013-18) Global Multiple Sclerosis Market: Trends and Opportunities (2013-18) Scope of the Report The report titled Global Multiple Sclerosis Market: Trends & Opportunities (2013-18) provides an insight into the

More information

Office of Medical Assistance (OMA) P&T Committee Meeting Minutes

Office of Medical Assistance (OMA) P&T Committee Meeting Minutes Office of Medical Assistance (OMA) P&T Committee Meeting Minutes January 9, 2013 Lazarus Building, 50 W. Town St., Columbus, OH 43215 Committee members present: Susan Baker, CNS; Suzanne Eastman, RPh;

More information

Student is then required to administer the medications following the 8 Rights.

Student is then required to administer the medications following the 8 Rights. PNSG 2016: Medical Surgical Nursing II Medication Simulation Laboratory Guidelines Objective: To enhance student medication administration experience by administering multiple medications to multiple patients

More information

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

More information

OVERACTIVE BLADDER DIAGNOSIS AND TREATMENT OF OVERACTIVE BLADDER IN ADULTS:

OVERACTIVE BLADDER DIAGNOSIS AND TREATMENT OF OVERACTIVE BLADDER IN ADULTS: 2014 OVERACTIVE BLADDER DIAGNOSIS AND TREATMENT OF OVERACTIVE BLADDER IN ADULTS: AUA/SUFU Guideline (2012); Amended (2014) For Primary Care Providers OVERACTIVE BLADDER Diagnosis and Treatment of Overactive

More information

The Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool

The Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool The Pharmacological Management of Cancer Pain in Adults Clinical Audit Tool 2015 This clinical audit tool accompanies the Pharmacological Management of Cancer Pain in Adults NCEC National Clinical Guideline

More information

STAT Bulletin. Drug Therapy Guideline Updates. May 11, 2012 Volume: 18 Issue: 12

STAT Bulletin. Drug Therapy Guideline Updates. May 11, 2012 Volume: 18 Issue: 12 STAT Bulletin May 11, 2012 Volume: 18 Issue: 12 To: All primary care physicians and specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat What

More information

Opioid Addiction and Methadone: Myths and Misconceptions. Nicole Nakatsu WRHA Practice Development Pharmacist

Opioid Addiction and Methadone: Myths and Misconceptions. Nicole Nakatsu WRHA Practice Development Pharmacist Opioid Addiction and Methadone: Myths and Misconceptions Nicole Nakatsu WRHA Practice Development Pharmacist Learning Objectives By the end of this presentation you should be able to: Understand how opioids

More information

Clinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients

Clinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients Clinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients Developed by the Mid Atlantic Renal Coalition and the Kidney End of Life Coalition September 2009 This project was supported,

More information

Remicade (infliximab)

Remicade (infliximab) Criteria for approval Commercial Only Remicade (infliximab) Background: Tumor Necrosis Factor (TNF) alpha is one of two proinflammatory cytokines that appear to play a dominant role in the inflammatory

More information

UNIT VIII NARCOTIC ANALGESIA

UNIT VIII NARCOTIC ANALGESIA UNIT VIII NARCOTIC ANALGESIA Objective Review the definitions of Analgesic, Narcotic and Antagonistic. List characteristics of Opioid analgesics in terms of mechanism of action, indications for use and

More information

Policy for the issue of permits to prescribe Schedule 8 poisons

Policy for the issue of permits to prescribe Schedule 8 poisons Policy for the issue of permits to prescribe Schedule 8 poisons May 2011 Introduction The Victorian Drugs, Poisons and Controlled Substances (DPCS) legislation sets out certain circumstances when a medical

More information

Best Practices for Patients With Pain. Commonly Used Over the Counter (OTC) Pain Relievers 5/15/2015

Best Practices for Patients With Pain. Commonly Used Over the Counter (OTC) Pain Relievers 5/15/2015 Faculty Best Practices for Patients With Pain Nancy Bishop, RPh Assistant State Pharmacy Director Alabama Department of Public Health Satellite Conference and Live Webcast Wednesday, May 20, 2015 2:00

More information

A Healthesystems Clinical Analysis. Insidious Incrementalism of Opioid Use in Workers Compensation

A Healthesystems Clinical Analysis. Insidious Incrementalism of Opioid Use in Workers Compensation A Healthesystems Clinical Analysis Insidious Incrementalism of Opioid Use in Workers Compensation Prescription opioid use in the United States has grown significantly over the past 20 years. In 1991, there

More information

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International

More information

Cancer Pain Role Model Program Case Studies and Faculty Guides. Wisconsin Cancer Pain Initiative Madison, Wisconsin

Cancer Pain Role Model Program Case Studies and Faculty Guides. Wisconsin Cancer Pain Initiative Madison, Wisconsin Cancer Pain Role Model Program Case Studies and Faculty Guides Wisconsin Cancer Pain Initiative Madison, Wisconsin Developed by: David Weissman, MD June L. Dahl, PhD WISCONSIN CANCER PAIN INITIATIVE CANCER

More information

Lemtrada (alemtuzumab)

Lemtrada (alemtuzumab) Lemtrada (alemtuzumab) Policy Number: 5.02.517 Last Review: 08/2015 Origination: 08/2015 Next Review: 08/2016 Policy BCBSKC will provide coverage for Lemtrada (alemtuzumab) when it is determined to be

More information

Prescribed Drug Spending in Canada, 2013: A Focus on Public Drug Programs

Prescribed Drug Spending in Canada, 2013: A Focus on Public Drug Programs Prescribed Drug Spending in Canada, 2013: A Focus on Public Drug Programs Spending and Health Workforce Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the development

More information

Pain Control Aims. General principles of pain control. Basic pharmacokinetics. Case history demo. Opioids renal failure John Welsh 8/4/2010

Pain Control Aims. General principles of pain control. Basic pharmacokinetics. Case history demo. Opioids renal failure John Welsh 8/4/2010 Pain Control Aims General principles of pain control Basic pharmacokinetics Case history demo Opioids renal failure John Welsh 8/4/2010 Pain Control Morphine is gold standard treatment for moderate to

More information

Where Can I Buy Alli Uk

Where Can I Buy Alli Uk Where Can I Buy Alli Uk where can i purchase alli in canada alli slimming pills cheapest price alli purchase canada order alli diet pills online order alli online canada can you buy alli at boots where

More information

Medicare Part D Open Enrollment for 2014: Popular Plans Continue to Evolve

Medicare Part D Open Enrollment for 2014: Popular Plans Continue to Evolve Fact Sheet Medicare Part D Open Enrollment for 2014: Popular Plans Continue to Evolve By Leigh Purvis AARP Public Policy Institute AARP Public Policy Institute Premiums for many popular stand-alone Medicare

More information

Opioid Conversion Ratios - Guide to Practice 2013

Opioid Conversion Ratios - Guide to Practice 2013 Opioid s - Guide to Practice 2013 Released 1 st October 2013 2013. The EMR PCC grants permission to reproduce parts of this publication for clinical and educational use only, provided that the Eastern

More information

Indocin Pda Closure. indocin suppository storage. indocin 50mg. indocin tablets. indocin sr capsules. indocin headache treatment

Indocin Pda Closure. indocin suppository storage. indocin 50mg. indocin tablets. indocin sr capsules. indocin headache treatment Indocin Pda Closure indocin suppository storage indocin 50mg indocin tablets indocin sr capsules indocin headache treatment indocin ivh prophylaxis indocin for gout indocin pda closure can indocin get

More information

Opioid Analgesics. Week 19

Opioid Analgesics. Week 19 Opioid Analgesics Week 19 Analgesic Vocabulary Analgesia Narcotic Opiate Opioid Agonist Antagonist Narcotic Analgesics Controlled substances Opioid analgesics derived from poppy Opiates include morphine,

More information

May 31, 2013. Ms. Debra Lansey American College of Physicians 190 North Independence Mall West Philadelphia, PA 19106

May 31, 2013. Ms. Debra Lansey American College of Physicians 190 North Independence Mall West Philadelphia, PA 19106 P.O. Box 30449 Salt Lake City, UT 84130-0449 May 31, 2013 Ms. Debra Lansey American College of Physicians 190 North Independence Mall West Philadelphia, PA 19106 Re: Pharmacy Benefit Coverage Changes Effective

More information

ATTENTION- DEFICIT HYPERACTIVITY DISORDER (ADHD) QUANTITY LIMITATION UTILIZATION MANAGEMENT CRITERIA

ATTENTION- DEFICIT HYPERACTIVITY DISORDER (ADHD) QUANTITY LIMITATION UTILIZATION MANAGEMENT CRITERIA ATTENTION- DEFICIT HYPERACTIVITY DISORDER (ADHD) QUANTITY LIMITATION UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: Stimulants and Non-Stimulants BRAND (generic) NAMES: Adderall (amphetamine/dextroamphetamine)

More information

Alla chme nl A EFFECTIVE 07/01/2014 BUREAU FOR MEDICAL SERVICES WEST VIRGINIA MEDICAID PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

Alla chme nl A EFFECTIVE 07/01/2014 BUREAU FOR MEDICAL SERVICES WEST VIRGINIA MEDICAID PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA A. Re-Review 1. Bethkis ANTIBIOTICS, INHALED BETHKIS (tobramycin) TOBI (tobramycin) 2. Effient CAYSTON (aztreonam) TOBI POOHALER tobramycin PLATELET AGGREGATION INHIBITORS AGGRENOX (dipyridamole/asa) BRIUNTA

More information

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Medication Policy Manual Policy No: dru376 Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective

More information

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

More information

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine

More information

AGS. PAIN MANAGEMENT FOR THE SURGICAL RESIDENT (in 30 min or less)

AGS. PAIN MANAGEMENT FOR THE SURGICAL RESIDENT (in 30 min or less) AGS PAIN MANAGEMENT FOR THE SURGICAL RESIDENT (in 30 min or less) THE AMERICAN GERIATRICS SOCIETY Geriatrics Health Professionals. Leading change. Improving care for older adults. CASE PRESENTATION 46-year-old

More information

MUSC Opioid Analgesic Comparison Chart

MUSC Opioid Analgesic Comparison Chart MUSC Opioid Analgesic Comparison Chart Approved by the Pharmacy and Therapeutics Committee (February 2006, November 2009, March 2010, December 2011) Prepared by the MUSC Department of Pharmacy Services

More information

Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company

Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company PRESCRIPTION DRUG RIDER This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health

More information

Medications for MULTIPLE SCLEROSIS Student Version

Medications for MULTIPLE SCLEROSIS Student Version Medications for MULTIPLE SCLEROSIS Student Version DEH 2300 Valencia Community College Summer: 2006-14 Sandra C. Pendergraft DEFINITION / PATHOPHYSIOLOGY Chronic, frequently progressive disease of CNS

More information